Skip to content
Biodatica
Start free

Celgene

Phoenix, Arizona

OncologyantibodyPhase IIIListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants

5d agoTrial registeredJul 14, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jan 5, 2027

    Healthy Volunteers · NOT_YET_RECRUITING · sponsor: Celgene · A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants

    ClinicalTrials.gov · NCT07700329 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Dec 15, 2025

    Healthy Volunteers · RECRUITING · sponsor: Celgene · A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

    ClinicalTrials.gov · NCT07242781 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Jun 9, 2025

    Agitation, Alzheimer Disease · RECRUITING · sponsor: Celgene · Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    ClinicalTrials.gov · NCT06808984 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Jun 5, 2025

    Multiple Sclerosis Spasticity · RECRUITING · sponsor: Celgene · A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    ClinicalTrials.gov · NCT06782490 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Aug 15, 2024

    Hepatic Impairment, Healthy Volunteers · COMPLETED · sponsor: Celgene · Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

    ClinicalTrials.gov · NCT06535399 (opens the source filing in a new tab)

  6. Trial

    PHASE3 registered

    Jun 19, 2024

    Large B-cell Lymphoma · ACTIVE_NOT_RECRUITING · sponsor: Celgene · Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

    ClinicalTrials.gov · NCT06356129 (opens the source filing in a new tab)

  7. Trial

    PHASE1 registered

    May 30, 2024

    Healthy Volunteers · COMPLETED · sponsor: Celgene · A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

    ClinicalTrials.gov · NCT06433505 (opens the source filing in a new tab)

  8. Trial

    PHASE1 registered

    Mar 21, 2024

    Renal Impairment · COMPLETED · sponsor: Celgene · A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

    ClinicalTrials.gov · NCT06318676 (opens the source filing in a new tab)

  9. Trial

    PHASE1 registered

    Feb 27, 2024

    Multiple Myeloma · TERMINATED · sponsor: Celgene · A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT06163898 (opens the source filing in a new tab)

  10. Trial

    PHASE3 registered

    Sep 20, 2022

    Relapsed or Refractory Multiple Myeloma · RECRUITING · sponsor: Celgene · A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    ClinicalTrials.gov · NCT05519085 (opens the source filing in a new tab)

  11. Trial

    PHASE3 registered

    Nov 11, 2021

    Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting · COMPLETED · sponsor: Celgene · Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

    ClinicalTrials.gov · NCT05028634 (opens the source filing in a new tab)

  12. Trial

    PHASE1 registered

    Oct 5, 2021

    Multiple Myeloma · TERMINATED · sponsor: Celgene · Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT04975399 (opens the source filing in a new tab)

  13. Trial

    PHASE1 registered

    Nov 11, 2020

    Lymphoma · TERMINATED · sponsor: Celgene · A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

    ClinicalTrials.gov · NCT04464798 (opens the source filing in a new tab)

  14. Trial

    PHASE3 registered

    Aug 12, 2019

    Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis · RECRUITING · sponsor: Celgene · A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

    ClinicalTrials.gov · NCT04064060 (opens the source filing in a new tab)

  15. Trial

    PHASE1/PHASE2 registered

    May 20, 2019

    Lymphoma, Non-Hodgkin · ACTIVE_NOT_RECRUITING · sponsor: Celgene · A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

    ClinicalTrials.gov · NCT03930953 (opens the source filing in a new tab)

  16. Trial

    PHASE3 registered

    Apr 16, 2019

    Multiple Myeloma · COMPLETED · sponsor: Celgene · Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

    ClinicalTrials.gov · NCT03651128 (opens the source filing in a new tab)

  17. Trial

    PHASE3 registered

    Jun 27, 2018

    Crohn Disease · TERMINATED · sponsor: Celgene · A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

    ClinicalTrials.gov · NCT03464097 (opens the source filing in a new tab)

  18. Trial

    PHASE2 registered

    Dec 13, 2017

    Multiple Myeloma · COMPLETED · sponsor: Celgene · Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT03361748 (opens the source filing in a new tab)

  19. Trial

    Study registered

    Mar 31, 2017

    Multiple Myeloma · COMPLETED · sponsor: Celgene · A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

    ClinicalTrials.gov · NCT03106324 (opens the source filing in a new tab)

  20. Trial

    PHASE2 registered

    Oct 22, 2015

    Hematologic Neoplasm, Neoplasms, Hematologic Malignancies · COMPLETED · sponsor: Celgene · A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

    ClinicalTrials.gov · NCT02494258 (opens the source filing in a new tab)

  21. Trial

    PHASE2 registered

    Oct 9, 2015

    Carcinoma, Non-Small-Cell Lung · COMPLETED · sponsor: Celgene · Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

    ClinicalTrials.gov · NCT02546986 (opens the source filing in a new tab)

  22. Trial

    Study registered

    Feb 20, 2015

    Multiple Myeloma · COMPLETED · sponsor: Celgene · Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

    ClinicalTrials.gov · NCT02555839 (opens the source filing in a new tab)

  23. Trial

    Study registered

    Dec 12, 2013

    Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute · TERMINATED · sponsor: Celgene · Connect® Myeloid Disease Registry

    ClinicalTrials.gov · NCT01688011 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources